Tag: bipolar

  • Psych Meds Are Not the Enemy. Bad Medicine Is

    Psych Meds Are Not the Enemy. Bad Medicine Is

    There is a dangerous difference between criticizing bad psychiatric practice and stigmatizing psychiatric illness.

    I have criticized aspects of psychiatry many times. I believe our field should be open to critique. We should question our prescribing habits. We should challenge lazy diagnosis. We should acknowledge when medications are used too quickly, continued too long, or substituted for the deeper work of psychotherapy, lifestyle change, social support, and careful clinical formulation.

    Psychiatry should never be above criticism.

    But criticism of psychiatric practice is not the same thing as denying the legitimacy of psychiatric illness.

    And right now, that line is being blurred.

    Serious Mental Illness Is Real

    One thing you will never hear me say is that psychiatric disease is not real.

    Schizophrenia is real.
    Bipolar disorder is real.
    Severe major depression is real.
    Catatonia is real.
    Psychotic depression is real.
    Obsessive-compulsive disorder can be profoundly disabling.
    Posttraumatic stress disorder can devastate a person’s life.

    These are not character flaws. They are not weakness. They are not simply failures of lifestyle, discipline, resilience, spirituality, or mindset.

    They are legitimate medical illnesses.

    That does not mean every painful experience is a disease. It does not mean every person who is grieving, anxious, overwhelmed, lonely, or struggling needs a diagnosis or a medication. In fact, one of the most important tasks in psychiatry is knowing the difference.

    Some people need medication.

    Some people need psychotherapy.

    Some people need sleep, exercise, nutrition, structure, social connection, housing, safety, meaning, accountability, or community.

    Many people need several of these at the same time.

    The goal is not to medicalize all suffering. The goal is to recognize real illness when it is present and treat it with the seriousness it deserves.

    The Problem Is Not “Medication”

    Psychiatric medications are often discussed as if they are inherently suspicious.

    But medication is not the enemy.

    Bad medicine is.

    A medication can be life-changing when used for the right condition, in the right person, at the right time, for the right reason.

    The same medication can be harmful when used carelessly, without a clear diagnosis, without follow-up, without discussion of risks and benefits, or without a plan for reassessment.

    That is not unique to psychiatry.

    Antibiotics can be lifesaving, but inappropriate antibiotic use causes harm. Opioids can be appropriate in some clinical contexts, but reckless prescribing devastated communities. Steroids can be powerful tools, but long-term unnecessary use can create major problems.

    The issue is not whether medications are “good” or “bad.”

    The issue is whether we are practicing medicine well.

    Deprescribing Matters, But It Is Not a Mental Health Policy

    Deprescribing is important.

    Every psychiatrist I know has experience reducing, simplifying, or stopping medications when the risks outweigh the benefits or when the original indication no longer makes sense.

    This is not a fringe idea. It is part of daily psychiatric practice.

    We stop medications that are not helping.
    We reduce unnecessary polypharmacy.
    We simplify regimens when possible.
    We monitor side effects.
    We reassess diagnoses.
    We talk with patients about what still makes sense.

    Good psychiatry includes deprescribing.

    But deprescribing alone will not solve the mental health crisis.

    People cannot deprescribe their way out of a lack of psychiatric beds. They cannot deprescribe their way out of months-long waitlists. They cannot deprescribe their way out of poverty, homelessness, trauma, addiction, loneliness, or a collapsing continuum of care.

    And they cannot deprescribe their way out of schizophrenia, mania, catatonia, psychotic depression, or severe melancholic depression.

    When we frame the mental health crisis primarily as a problem of overprescribing, we oversimplify a system failure.

    We ignore the shortage of psychiatrists. We ignore the lack of access to psychotherapy. We ignore inadequate visit times, fragmented care, insurance barriers, emergency departments boarding psychiatric patients for days, and the near disappearance of a true continuum of care.

    Those are not solved by telling people to take fewer medications.

    The Risk of Stigma Dressed Up as Reform

    My concern is not that we are talking about prescribing quality. We should be talking about that.

    My concern is that the rhetoric around psychiatric medications often sends a dangerous message to people who already feel ashamed.

    Many patients with serious mental illness already struggle with the idea of needing medication.

    They worry it means they are weak.
    They worry it means they are broken.
    They worry it means they are dependent.
    They worry it means they are not trying hard enough.
    They worry others will see them differently.

    When public conversations frame psychiatric medications as the central villain, those patients hear something very different from “we need better prescribing.”

    They hear:

    You are dependent.
    You are addicted.
    You are taking the easy way out.
    You should be able to fix this naturally.
    You are the problem.

    That is not empowerment.

    That is stigma.

    And for some patients, that stigma can be dangerous. It can lead people to stop medications abruptly, avoid treatment, disengage from care, relapse, or delay help until a crisis occurs.

    Of course patients should be informed. Of course they should understand risks and benefits. Of course they should have a voice in treatment decisions.

    But informed consent should not become fear-based messaging. And reform should not become another way of shaming people with serious psychiatric illness.

    Better Medicine Means Holding Two Truths

    The future of psychiatry depends on our ability to hold two truths at the same time.

    First, psychiatric illness is real and can be devastating.

    Second, psychiatry must be careful not to overdiagnose, overprescribe, or turn normal human suffering into lifelong pathology.

    Both truths matter.

    If we only emphasize the first, we risk medicalizing everything.

    If we only emphasize the second, we risk abandoning people with serious illness.

    Real psychiatric care lives in the tension between those truths.

    It requires humility. It requires careful diagnosis. It requires honest conversations about uncertainty. It requires medication when appropriate, psychotherapy when appropriate, lifestyle intervention when appropriate, social support when appropriate, neuromodulation when appropriate, and deprescribing when appropriate.

    It also requires us to say clearly that some people need medication, and that needing medication is not a moral failure.

    The Goal Is Better Medicine

    The goal is not to prescribe more.

    The goal is not to prescribe less.

    The goal is to prescribe better.

    Better diagnosis.
    Better informed consent.
    Better follow-up.
    Better access to psychotherapy.
    Better use of lifestyle interventions.
    Better systems of care.
    Better deprescribing when medications are no longer needed.
    Better protection for people whose medications are the reason they are alive, stable, working, parenting, studying, and functioning.

    We do not fix psychiatry by pretending psychiatric medications are always the answer.

    But we also do not fix psychiatry by pretending they are the enemy.

    Psych meds are not the enemy.

    Bad medicine is.

  • New JAMA Study Challenges Previous Concerns About Valproate and Paternal Risk

    New JAMA Study Challenges Previous Concerns About Valproate and Paternal Risk

    What we thought we knew may not hold up under scrutiny.

    A recent JAMA Psychiatry study titled “Disorders and Paternal Use of Valproate During Spermatogenesis” has delivered surprising news:

    There was no increased risk of neurodevelopmental disorders in children whose fathers were taking valproic acid around the time of conception.

    This finding directly challenges earlier observational data that suggested a possible link, leading to cautionary guidance against prescribing valproate to men of reproductive age. But now, with a large, well-conducted study showing no signal of harm, we’re left reconsidering that initial recommendation.

    As clinicians, we must remember:
    🔍 Association is not causation.
    🚧 Observational studies, while valuable, can mislead when confounding variables aren’t fully accounted for.
    📚 Evidence evolves—and so must our clinical guidance.

    This study not only impacts how we think about valproate use in men but also serves as a critical reminder about the limits of inference from non-randomized data.

    👉 For patients with bipolar disorder or epilepsy who benefit from valproate, this offers some reassurance. We may not need to withhold an effective treatment based on unconfirmed reproductive risks.

    📌 Bottom line: Always be skeptical. Always be curious. Always be willing to revise your practice when the data say it’s time.

    link to the study: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2834363

  • 💥 Time to Rethink Valproate in Acute Mania

    Valproate continues to be overvalued in the treatment of acute mania—and it doesn’t work as well as many assume.

    Part of the problem? A single overhyped study, cleverly marketed by the pharmaceutical company, has shaped decades of prescribing habits and continues to be taught to psychiatry residents as gold-standard evidence.

    But the data tells a different story.
    The BALANCE study (British study of Lithium +/− Valproate) showed no significant long-term benefit to adding valproate to lithium over a 2-year period in bipolar disorder.

    It’s time we stop relying on outdated assumptions and start practicing based on robust, long-term outcomes—not industry narratives.

    📚 Evidence over tradition.
    🧠 Teach residents the full picture.
    💊 Prescribe with precision.

  • Is olanzapine overrated for acute mania?

    🧠 Olanzapine has built a reputation as a heavy-hitter for treating acute manic episodes—but the data tells a more modest story.

    In one key study comparing olanzapine vs. placebo over 3 weeks:

    • Response rate: 55% (olanzapine) vs. 30% (placebo)
    • Remission rate: 18% (olanzapine) vs. 7% (placebo)

    That’s a 25% absolute difference in response and just an 11% difference in remission—not exactly blockbuster results.

    This doesn’t mean olanzapine has no role in mania treatment. But it’s time to recalibrate our expectations and remain clear-eyed about what the data shows.

    💊 Efficacy matters. So does the narrative we build around our tools.

  • Rapid cycling ≠ lithium failure

    There’s a persistent myth in psychiatry that lithium doesn’t work for bipolar disorder with rapid cycling.

    🧠 But here’s the truth:
    Multiple literature reviews show lithium performs just as well as other antimanic agents in rapid cyclers. The issue isn’t lithium—it’s that rapid cycling is simply harder to treat overall.

    Let’s stop excluding one of our most effective mood stabilizers based on outdated or anecdotal thinking. Patients with rapid cycling deserve full access to evidence-based treatment options—including lithium.

  • Dexmedetomidine for Acute Agitation in Bipolar and Schizophrenia: Worth the Hype?

    I recently received a great question about the use of dexmedetomidine for acute agitation. With its recent FDA approval for agitation associated with bipolar disorder and schizophrenia, it’s only natural to wonder: is this the new go-to treatment, or just another overhyped medication?

    Let’s start with the obvious. New medications almost always come with a hefty price tag. That cost is only justifiable if they outperform existing options in either efficacy or safety—and in this case, dexmedetomidine falls short on both fronts.

    Current data suggest it does not provide superior outcomes when compared to existing, well-established medications like lorazepam, haloperidol, or olanzapine. And it brings along its own baggage: bradycardia, hypotension, and sedation-related complications that can be clinically significant, especially in medically complex patients.

    When you combine the high cost with a safety profile that raises some red flags—and no clear advantage in efficacy—it becomes hard to justify widespread use.

    For now, I’d place dexmedetomidine in the “hype” category. We already have effective, affordable options with strong track records in managing acute agitation. Until further data prove otherwise, there’s little reason to switch.

  • 🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

    🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

    A new study trained an AI model on 24,000+ electronic health records (EHRs) to predict whether a patient would develop schizophrenia or bipolar disorder. The results? 🤔

    🔍 The XGBoost machine learning model showed better performance for schizophrenia than bipolar disorder.
    📊 It achieved an AUC of 0.70 on training data and 0.64 on the test set.
    ⚠️ But here’s the catch: despite 96.3% specificity, the model’s sensitivity was just 9.3%, meaning it missed the vast majority of cases.

    💡 Bottom Line: AI in psychiatry is promising, but we’re not at the point where a model like this could reliably flag patients at risk. High specificity sounds great—until you realize the trade-off is missing 90%+ of those who actually transition to schizophrenia or bipolar disorder.

    Will future AI tools get better at predicting these life-altering conditions? Time (and data) will tell. ⏳

  • 🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

    🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

    A new study trained an AI model on 24,000+ electronic health records (EHRs) to predict whether a patient would develop schizophrenia or bipolar disorder. The results? 🤔

    🔍 The XGBoost machine learning model showed better performance for schizophrenia than bipolar disorder.
    📊 It achieved an AUC of 0.70 on training data and 0.64 on the test set.
    ⚠️ But here’s the catch: despite 96.3% specificity, the model’s sensitivity was just 9.3%, meaning it missed the vast majority of cases.

    💡 Bottom Line: AI in psychiatry is promising, but we’re not at the point where a model like this could reliably flag patients at risk. High specificity sounds great—until you realize the trade-off is missing 90%+ of those who actually transition to schizophrenia or bipolar disorder.

    Will future AI tools get better at predicting these life-altering conditions? Time (and data) will tell. ⏳

  • The Most Commonly Prescribed Medication for Bipolar Disorder… But Is It the Best?

    The Most Commonly Prescribed Medication for Bipolar Disorder… But Is It the Best?

    When it comes to bipolar disorder, the most commonly prescribed medication isn’t necessarily the most effective.Many clinicians default to prescribing quetiapine, valproate, or lamotrigine, yet lithium remains the gold standardfor long-term treatment.

    So, why is lithium often overlooked? Despite decades of evidence supporting its unmatched efficacy in preventing relapse, reducing suicide risk, and stabilizing mood long-term, lithium is underprescribed due to concerns over side effects, monitoring requirements, and physician discomfort with its use.

    🔹 What Do the RCTs Say About Lithium?

    ✅ BALANCE Trial (2010) – The landmark study comparing lithium vs. valproate vs. combination therapy found that lithium monotherapy was superior to valproate in preventing relapse into both manic and depressive episodes (Geddes et al., 2010).

    ✅ NIMH STEP-BD Trial (2005) – Among mood stabilizers, lithium significantly reduced suicide risk, a benefit not shared by other common treatments (Goodwin et al., 2003).

    ✅ Cade’s Legacy and Beyond – Multiple meta-analyses confirm that lithium reduces relapse rates and is the only mood stabilizer with strong anti-suicidal effects (Cipriani et al., 2005).

    🚨 The Bottom Line? Lithium is STILL the most effective long-term treatment for bipolar disorder, yet it is often underutilized. Instead, newer and more expensive alternatives are frequently prescribed—even when they lack lithium’s robust evidence base.

    Yes, lithium requires monitoring. Yes, it comes with side effects. But for patients with bipolar disorder, choosing the right medication can mean the difference between stability and relapse, life and death.

    Let’s start prescribing based on data, not convenience. 🔥

  • 🚨 Mania with Mixed Features: The Ultimate Mood Storm 🌪️

    🚨 Mania with Mixed Features: The Ultimate Mood Storm 🌪️

    Bipolar mania is intense—but when mixed features are present, it’s a whole different beast. Imagine sky-high energy ⚡ + crushing despair 😞 at the same time. That’s mixed mania—one of the most challenging and high-risk mood states in psychiatry.

    🔍 What Does It Look Like?

    ✅ Racing thoughts 🏎️ + Hopelessness 😔
    ✅ Insomnia for days 🌙 + Feeling exhausted 😴
    ✅ Irritability 🔥 + Tearfulness 😢
    ✅ Grandiosity 👑 + Suicidal thoughts 🚨
    ✅ Restless energy ⚡ + No pleasure in anything ❌

    🚑 Why It’s High Risk

    Patients with mania + mixed features have:
    ⚠️ Higher suicide risk than pure mania
    ⚠️ More agitation & impulsivity
    ⚠️ Less response to traditional mood stabilizers

    🛑 Treatment Challenges

    ❌ Antidepressants can worsen symptoms
    ✅ Mood stabilizers (lithium, valproate) & atypical antipsychotics (quetiapine, olanzapine, lurasidone) are key
    ✅ Careful monitoring is essential

    💡 Takeaway: Mixed mania isn’t just “agitated depression” or “irritable mania”—it’s a unique, dangerous mood state that requires urgent intervention. Recognizing it early can save lives.

    Have you encountered mixed mania in practice? Let’s discuss! 👇